APO Research
Talk to an analyst

APO RESEARCH · REPORT

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025185 pages

Choose your research edition.

Industry ResearchIrritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs include Allergan, Amneal Pharms, Astellas Pharmaceuticals, Bausch Health, Sebela Pharmaceuticals and Pharscin Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Company

Allergan

Amneal Pharms

Astellas Pharmaceuticals

Bausch Health

Sebela Pharmaceuticals

Pharscin Pharma

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type

XIFAXAN

Lotronex

Viberzi

Other

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application

Hospitals Pharmacy

Retail Pharmacy

Other

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends Table 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers Table 3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges Table 4. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (K Pcs) & (2021-2026) Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Sales Price (US$/Pcs) of Manufacturers (2021-2026) Table 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers, Product Type & Application Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of XIFAXAN Table 17. Major Manufacturers of Lotronex Table 18. Major Manufacturers of Viberzi Table 19. Major Manufacturers of Other Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type 2021 VS 2025 VS 2032 (K Pcs) Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K Pcs) Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2027-2032) & (K Pcs) Table 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2021-2026) Table 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2027-2032) Table 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Pcs) Table 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2026) & (K Pcs) Table 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2027-2032) & (K Pcs) Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospitals Pharmacy Table 31. Major Manufacturers of Retail Pharmacy Table 32. Major Manufacturers of Other Table 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application 2021 VS 2025 VS 2032 (K Pcs) Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K Pcs) Table 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2027-2032) & (K Pcs) Table 36. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2021-2026) Table 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2027-2032) Table 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Pcs) Table 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2026) & (K Pcs) Table 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2027-2032) & (K Pcs) Table 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021-2026) & (K Pcs) Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2021-2026) Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecasted by Region (2027-2032) & (K Pcs) Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 49. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K Pcs) Table 50. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032) & (K Pcs) Table 51. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K Pcs) Table 53. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032) & (K Pcs) Table 54. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 55. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K Pcs) Table 56. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032) & (K Pcs) Table 57. South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 58. South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K Pcs) Table 59. South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032) & (K Pcs) Table 60. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2027-2032) Table 65. Allergan Company Information Table 66. Allergan Business Overview Table 67. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 69. Allergan Recent Development Table 70. Amneal Pharms Company Information Table 71. Amneal Pharms Business Overview Table 72. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 74. Amneal Pharms Recent Development Table 75. Astellas Pharmaceuticals Company Information Table 76. Astellas Pharmaceuticals Business Overview Table 77. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 79. Astellas Pharmaceuticals Recent Development Table 80. Bausch Health Company Information Table 81. Bausch Health Business Overview Table 82. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 84. Bausch Health Recent Development Table 85. Sebela Pharmaceuticals Company Information Table 86. Sebela Pharmaceuticals Business Overview Table 87. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 89. Sebela Pharmaceuticals Recent Development Table 90. Pharscin Pharma Company Information Table 91. Pharscin Pharma Business Overview Table 92. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 94. Pharscin Pharma Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List Table 98. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Image Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (2021-2032) & (K Pcs) Figure 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Top 5 and 10 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. XIFAXAN Image Figure 9. Lotronex Image Figure 10. Viberzi Image Figure 11. Other Image Figure 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Pcs) Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Pcs) Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2021-2032) Figure 18. Hospitals Pharmacy Image Figure 19. Retail Pharmacy Image Figure 20. Other Image Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Pcs) Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Pcs) Figure 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 28. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 30. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 31. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 32. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 33. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 35. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 36. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 37. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 38. Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 39. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 40. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2021-2032) Figure 41. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 42. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 43. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 44. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 45. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 46. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 47. South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 48. South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 50. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 51. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 52. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 53. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 54. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 55. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 56. Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2032) & (K Pcs) Figure 57. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • XIFAXAN
  • Lotronex
  • Viberzi
  • Other
Applications
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Other
Companies covered
  • Allergan
  • Amneal Pharms
  • Astellas Pharmaceuticals
  • Bausch Health
  • Sebela Pharmaceuticals
  • Pharscin Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
  1. 2.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
  2. 2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers
  3. 2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges
  4. 2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints
3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Manufacturers
  1. 3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Tier 1, Tier 2, and Tier 3
4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Type
  1. 4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Type Introduction
  2. 4.1.1 XIFAXAN
  3. 4.1.2 Lotronex
  4. 4.1.3 Viberzi
  5. 4.1.4 Other
  6. 4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
  7. 4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type
  11. 4.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2021-2032)
5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Application
  1. 5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Application Introduction
  2. 5.1.1 Hospitals Pharmacy
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application
  6. 5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
  10. 5.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2021-2032)
6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
  1. 6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
  1. 7.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
  2. 7.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032)
  8. 7.2.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Amneal Pharms
  8. 8.2.1 Amneal Pharms Company Information
  9. 8.2.2 Amneal Pharms Business Overview
  10. 8.2.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  12. 8.2.5 Amneal Pharms Recent Developments
  13. 8.3 Astellas Pharmaceuticals
  14. 8.3.1 Astellas Pharmaceuticals Company Information
  15. 8.3.2 Astellas Pharmaceuticals Business Overview
  16. 8.3.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  18. 8.3.5 Astellas Pharmaceuticals Recent Developments
  19. 8.4 Bausch Health
  20. 8.4.1 Bausch Health Company Information
  21. 8.4.2 Bausch Health Business Overview
  22. 8.4.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  24. 8.4.5 Bausch Health Recent Developments
  25. 8.5 Sebela Pharmaceuticals
  26. 8.5.1 Sebela Pharmaceuticals Company Information
  27. 8.5.2 Sebela Pharmaceuticals Business Overview
  28. 8.5.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  30. 8.5.5 Sebela Pharmaceuticals Recent Developments
  31. 8.6 Pharscin Pharma
  32. 8.6.1 Pharscin Pharma Company Information
  33. 8.6.2 Pharscin Pharma Business Overview
  34. 8.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  36. 8.6.5 Pharscin Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Analysis
  2. 9.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process
  6. 9.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
  9. 9.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst